Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Aerovate Therapeutics Presents Baseline Data From Phase 2b Portion Of IMPAHCT Trial At ATS 2024 International Conference

Author: Benzinga Newsdesk | May 21, 2024 04:21pm

Baseline characteristics reflect a PAH population with significant disease

 

Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024

Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally

Posted In: AVTE